You are here: Home ยป Archives for health

Kensana Health Lands $120 million from GEM, Fuelling a Global Plant Based Medicine Revolution

NEW YORK, Sept. 19, 2025 (GLOBE NEWSWIRE) — Kensana Health Inc. (“Kensana”) today announced it has entered into a share subscription facility of up to $120 million with GEM Global Yield LLC SCS (“GEM”), a Luxembourg–based alternative investment group. Under the agreement, GEM will provide Kensana up to $120 million for a 36–month period following a public listing of Kensana’s ordinary shares (“Investment Period”).

According to the agreement’s terms, Kensana will not be obligated to draw down the full $120 million but can do so in part or in whole at its discretion. Kensana can also set a threshold price as the lowest price at which Kensana may issue shares to GEM under a given drawdown. Kensana will control both the timing and amount of all drawdowns and will issue common shares to GEM on each drawn down from the facility. GEM shall pay 90% of the average daily closing price during the pricing period, which is a 30–day period after Kensana delivers a draw–down notice to GEM. During the lifetime of the investment facility, GEM will not, directly or indirectly, effect any short sale of Kensana’s common shares. GEM is a long–only investor and will not engage in shorting, hedging, or the use of derivatives or synthetic instruments against Kensana’s common shares or the issuance of any warrants.

Ken Clement, founder of Kensana, commented: “It has been determined that 90% of the world’s drugs are synthetically copied from naturally occurring plant compounds. (Bade, et al., 2010. European Journal of Medicinal Chemistry) According to the WHO, up to 80% of the world’s population believes that traditional herbal medicines are safer and have fewer side effects than traditional synthetic pharmaceuticals. Kensana plans to transform modern medicine by integrating its proprietary Artificial Intelligence (AI)–enhanced technology to harness naturally occurring compounds for drug development. Since the COVID pandemic, global markets have had an insatiable appetite for everything natural which positions Kensana and its phytopharmaceutical platform to become a global leader in plant–based medicine. Kensana has already demonstrated this capability through the development of its first FDA drug candidate, KV23A, which has shown incredible efficacy in white label trials outlined in numerous peer–reviewed medical journals. The share subscription facility with GEM demonstrates investor confidence in Kensana’s prospects, as well as GEM’s strategic understanding and vision for emerging markets and industries. This facility will be a very effective financial instrument that will complement our other fundraising efforts ahead of our anticipated NASDAQ listing in 2026.”

About Kensana

Kensana, is a Canadian Phytopharmaceutical company that has created a proprietary Generation 4 AI–enhanced phytobioreactor platform (EMOB) which enables the company to assume leadership in a new industry: Phytopharmaceuticals. The EMOB platform allows Kensana to standardize and convert an abundance of naturally occurring plant and compounds into U.S. FDA registered pharmaceuticals with global respectability. Kensana’s first patented formula is entering an international FDA–registerable Phase 3 clinical trial. Uniquely risk–mitigated, the KV23a formula has already successfully proven safety and efficacy via therapeutic applications in a clinical setting. KV23a is Kensana’s first targeted FDA– registered product within a global chronic wound market worth $300 Billion USD. The Patented Chronic Wound Formula, KV23a, has Proven Medical Efficacy which has been demonstrated in Published peer reviewed medical journals validating KV23a and its efficacy while demonstrating no toxicity issues. Phytopharmaceuticals largely work by targeting specific receptors, interrupting disease pathways and disrupting pathogenic life cycles. The Kensana Platform, EMOB, has the ability to produce proprietary therapies as well as re–engineer synthetic drugs originally derived from natural plant compounds.

Kensana Health has a uniquely risk–mitigated business model and is currently entering a Series C Investment Round. For more information, please visit the website at www.kensana.health or contact Randy Uens at [email protected].

About GEM

GEM is a $3.4 billion, Luxembourg–based alternative investment group with offices in Paris, New York, and Nassau (Bahamas). GEM manages a diverse set of investment vehicles focused on emerging markets and has completed over 590 transactions in over 75 countries. Each investment vehicle has a different degree of operational control, risk–adjusted return, and liquidity profile. Its family of funds and investment vehicles provide GEM and its partners with exposure to Small–Mid Cap Management Buyouts, Private Investments in Public Equities and select venture investments. For more information: www.gemny.com


GLOBENEWSWIRE (Distribution ID 9532205)

Minovia Therapeutics Receives FDA Fast Track Designation for MNV-201 in Myelodysplastic Syndrome

HAIFA, Israel, Sept. 18, 2025 (GLOBE NEWSWIRE) — Minovia Therapeutics Ltd. (“Minovia” or the “Company”), a clinical–stage biotechnology company developing novel therapies to treat mitochondrial diseases and combat age–related decline, announces that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to the Company’s lead investigational compound, MNV–201 for Myelodysplastic Syndrome (MDS), a serious age–related hematopoietic disease. This designation is in addition to the existing FDA Fast Track and Rare Pediatric Disease Designations for MNV–201 in the treatment of Pearson Syndrome, an ultra–rare and life–threatening mitochondrial disorder affecting children and for which the Company is currently conducting a Phase 2 clinical trial.

“The Fast Track Designation in MDS is further validation of the urgency and potential for our science, which targets the mitochondria, a critical multi–functional organelle. FDA designations such as the FTD help us to decrease the potential time to market and provide additional benefits across the FDA process that, we expect, will prove both medically and financially valuable,” said Minovia Co–founder and CEO, Natalie Yivgi–Ohana, Ph.D.

FDA’s Fast Track Designation is designed to accelerate the development and review of therapies for serious or life–threatening conditions with unmet medical need. The designation provides Minovia with the opportunity for increased FDA interactions, potential eligibility for priority review, and the opportunity for a rolling submission of a future Biologics License Application (BLA) for MNV–201.  

The Company also recently announced entry into a definitive business combination agreement (the “Business Combination Agreement”) with Launch One Acquisition Corp. (Nasdaq: LPAA, “Launch One”), a publicly traded special purpose acquisition company. Following the expected closing of the transaction contemplated by this Business Combination Agreement (the “Business Combination”), projected for late 2025, the combined company will operate as Minovia Therapeutics and trade on Nasdaq under a new ticker symbol.

About MDS

MDS is defined by ineffective hematopoiesis resulting in blood cytopenia, and clonal instability with a risk of evolution to Acute Myeloid Leukemia (AML). Patients with MDS collectively have a high symptom burden and are also at risk of death from complications of cytopenia and AML. The goals of therapy for patients with MDS are to improve cytopenia, reduce disease–associated symptoms and the risk of disease progression and death, thereby improving both quality of life and lifespan. The median age at diagnosis of MDS is ~70 years, but surprisingly some of the Pearson Syndrome patients develop MDS in a much higher prevalence relative to the disease population. About 15% of the MDS patients will present with Sideroblastic Anemia, the most common symptom in Pearson Syndrome. Minovia developed novel blood biomarkers to measure mitochondrial health and has been able to demonstrate for the first time that MDS is presumably an age–related mitochondrial disease. As such, Minovia is currently conducting a Phase Ib study of MNV–201 in low–risk MDS patients. Six out of the nine expected patients in the study have been dosed so far.

About MNV–201

MNV–201 is a first–in–class cell therapy that uses Minovia’s proprietary Mitochondrial Augmentation Technology (MAT) to add healthy, energy–producing mitochondria into a patient’s own stem cells — aiming to restore organ function and improve health. In early–stage clinical studies, MAT has demonstrated a strong safety profile and signs of multi–system benefit in patients with Pearson Syndrome, including improvements in growth, muscle function, hematologic stability, and improved quality of life.

About Minovia Therapeutics

Minovia Therapeutics, chaired by John Cox, is a clinical–state biotechnology company working on treatments to replace dead or defective mitochondria with new healthy mitochondria, helping people with mitochondrial diseases and fighting aging. Minovia’s main treatment, MNV–201, is already being tested for Pearson Syndrome and Myelodysplastic Syndrome. Minovia is also developing ways to help people live longer, healthier lives. Based in Haifa, Israel, where it operates a GMP facility for mitochondrial drug substance and drug product manufacturing for clinical trials related to its therapy, Minovia is planning to expand operations to the U.S. For more information, visit www.minoviatx.com.

About Launch One Acquisition Corp.

Launch One Acquisition Corp. is a company set up to merge with and take public an exciting business in healthcare or technology. Listed on Nasdaq under the ticker LPAA, Launch One is led by experienced leaders who want to support game–changing solutions. For more information, contact Jurgen van de Vyver at [email protected].

Additional Information and Where to Find It

In connection with the Business Combination and the Business Combination Agreement, among Launch One, Minovia and Mito US One Ltd., a newly formed Israeli company limited by shares (“Pubco”), and certain other parties named therein. Launch One and Minovia intend to file relevant materials with the U.S. Securities and Exchange Commission (“SEC”), including a Registration Statement on Form F–4 of Pubco (the “Registration Statement”), which will include a proxy statement/prospectus of Launch One, and will file other documents regarding the proposed Business Combination with the SEC. This communication is not intended to be, and is not, a substitute for the proxy statement/prospectus or any other document that Launch One has filed or may file with the SEC in connection with the proposed Business Combination. The Registration Statement has not been filed or declared effective by the SEC. Following such filing and upon such declaration of effectiveness, the definitive proxy statement/prospectus contained within the Registration Statement and other relevant materials for the proposed Business Combination will be mailed or made available to stockholders of Launch One as of a record date to be established for voting on the proposed Business Combination.

Before making any voting or investment decision, investors and stockholders of Launch One are urged to carefully read, when they become available, the entire Registration Statement, the proxy statement/prospectus, and any other relevant documents filed with the SEC, as well as any amendments or supplements to these documents, and the documents incorporated by reference therein, because they will contain important information about Launch One, Minovia, Pubco and the proposed Business Combination . Launch One’s investors and stockholders and other interested persons will also be able to obtain copies of the Registration Statement, the preliminary proxy statement/prospectus, the definitive proxy statement/prospectus, other documents filed with the SEC that will be incorporated by reference therein, and all other relevant documents filed with the SEC by Launch One and/or Pubco in connection with the Business Combination, without charge, once available, at the SEC’s website at www.sec.gov, or by directing a request to Launch One or Minovia at the addresses set forth below.

Participants In the Solicitation

Launch One, Minovia, Pubco and their respective directors, executive officers, other members of management and employees may be deemed participants in the solicitation of proxies from Launch One’s stockholders with respect to the Business Combination. Investors and security holders may obtain more detailed information regarding the names, and interests in the Business Combination, of Launch One’s directors and officers in Pubco's and Launch One’s filings with the SEC, including, when filed with the SEC, the preliminary proxy statement/prospectus, the definitive proxy statement/prospectus, amendments and supplements thereto, and other documents filed with the SEC. Such information with respect to Minovia’s directors and executive officers will also be included in the proxy statement/prospectus. You may obtain free copies of these documents as described above under the heading “Additional Information and Where to Find It.”

Non–Solicitation

This press release is not a proxy statement or solicitation of a proxy, consent or authorization with respect to any securities or in respect of the potential transaction and shall not constitute an offer to sell or a solicitation of an offer to buy the securities of Launch One, Pubco, or Minovia, nor shall there be any sale of any such securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of the Securities Act of 1933, as amended.

Forward–Looking Statements

This press release includes certain statements that may be considered forward–looking statements within the meaning of the federal securities laws. Forward–looking statements include, without limitation, statements about future events or Minovia’s, Launch One's, or Pubco's future financial or operating performance. For example, statements regarding the development and regulatory approval of MNV–201, the implications of Fast Track Designation, RPD and PRVs and the timing of future clinical trials or potential applications are forward–looking statements. In some cases, you can identify forward–looking statements by terminology such as “may,” “should,” “could,” “might,” “plan,” “possible,” “project,” “strive,” “budget,” “forecast,” “expect,” “intend,” “will,” “estimate,” “anticipate,” “believe,” “predict,” “potential” or “continue,” or the negatives of these terms or variations of them or similar terminology.

These forward–looking statements regarding future events and the future results of Minovia or Launch One are based on current expectations, estimates, forecasts, and projections about the industry in which Minovia or Launch One operates, as well as the beliefs and assumptions of Minovia’s and Launch One's management. These forward–looking statements are only predictions and are subject to, without limitation, (i) known and unknown risks, including the risks and uncertainties indicated from time to time in the final prospectus of Launch One relating to its initial public offering filed with the SEC, including those under “Risk Factors” therein, and other documents filed or to be filed with the SEC by Launch One or Pubco; (ii) uncertainties; (iii) assumptions; and (v) other factors beyond Minovia’s or Launch One's control that are difficult to predict because they relate to events and depend on circumstances that will occur in the future. They are neither statements of historical fact nor promises or guarantees of future performance. Therefore, Minovia’s actual results may differ materially and adversely from those expressed or implied in any forward–looking statements and Minovia and Launch One therefore caution against relying on any of these forward–looking statements.

These forward–looking statements are based upon estimates and assumptions that, while considered reasonable by Minovia and its management, as the case may be, are inherently uncertain and are inherently subject to risks, variability and contingencies, many of which are beyond Minovia’s or Launch One's control. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: (i) the occurrence of any event, change or other circumstances that could give rise to the termination of the Business Combination Agreement and any subsequent definitive agreements with respect to the Business Combination; (ii) the outcome of any legal proceedings that may be instituted against Launch One, Minovia, Pubco, or others following the announcement of the Business Combination and any definitive agreements with respect thereto; (iii) the inability to complete the Business Combination due to the failure to obtain consents and approvals of the shareholders of Launch One and Minovia, to obtain financing to complete the Business Combination or to satisfy other conditions to closing, or delays in obtaining, adverse conditions contained in, or the inability to obtain necessary regulatory approvals required to complete the transactions contemplated by the Business Combination Agreement; (iv) changes to the proposed structure of the Business Combination that may be required or appropriate as a result of applicable laws or regulations or as a condition to obtaining regulatory approval of the Business Combination; (v) projections, estimates and forecasts of revenue and other financial and performance metrics, projections of market opportunity and expectations, and the estimated implied enterprise value of Minovia; (vi) Minovia’s ability to scale and grow its business, and the advantages and expected growth of Minovia; (vii) Minovia’s ability to source and retain talent, and the cash position of Minovia following closing of the Business Combination; (viii) the ability to meet stock exchange listing standards in connection with, and following, the consummation of the Business Combination; (ix) the risk that the Business Combination disrupts current plans and operations of Minovia as a result of the announcement and consummation of the Business Combination; (x) the ability to recognize the anticipated benefits of the Business Combination, which may be affected by, among other things, competition, the ability of Minovia to grow and manage growth profitably, maintain key relationships and retain its management and key employees; (xi) costs related to the Business Combination; (xii) changes in applicable laws, regulations, political and economic developments; (xiii) the possibility that Minovia may be adversely affected by other economic, business and/or competitive factors; (xiv) Minovia’s estimates of expenses and profitability; (xv) the failure to realize estimated shareholder redemptions, purchase price and other adjustments; and (xvi) other risks and uncertainties set forth in the filings by Launch One and Minovia with the SEC. There may be additional risks that neither Launch One nor Minovia presently know or that Launch One and Minovia currently believe are immaterial that could also cause actual results to differ from those contained in the forward–looking statements. Any forward–looking statements made by or on behalf of Launch One or Minovia speak only as of the date they are made. Neither Launch One nor Minovia undertakes any obligation to update any forward–looking statements to reflect any changes in their respective expectations with regard thereto or any changes in events, conditions or circumstances on which any such statements are based.  

Contact

Minovia Therapeutics Ltd.
Natalie Yivgi Ohana, Co–Founder and CEO
+972–74–7039954
[email protected]

Launch One Acquisition Corp.
Jurgen van de Vyver
[email protected]
+1–510–692–9600

Investor Relations
Dave Gentry, CEO
RedChip Companies
+1–407–644–4256
[email protected]

Investor Relations
Jules Abraham
Managing Director, Communications
CORE IR
1–212–655–0924
[email protected]


GLOBENEWSWIRE (Distribution ID 9531105)

Entera Bio Presents Positive Effects of EB613 on Both Trabecular and Cortical Bone in Postmenopausal Women with Osteoporosis at ASBMR 2025

EB613 Demonstrates Significant Effects on Both Trabecular and Cortical Bone Compartments After Just 6 Months of Treatment in Phase 2 Study; Cortical Improvements Comparable to Injectable Teriparatide and Abaloparatide

Company Plans to Initiate Global Registrational Phase 3 Study Following July 2025 FDA Concurrence

Entera also Presented Promising Pharmacokinetic Data for Next–Gen EB613 Single Tablet Candidate as Potential Future Franchise Extension

JERUSALEM, Sept. 08, 2025 (GLOBE NEWSWIRE) — Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptides and proteins replacement therapies, today announced data selected for presentation at the American Society for Bone and Mineral Research (“ASBMR”) 2025 Annual Meeting in Seattle, Washington, for its lead program EB613 which is in late stage clinical development for post–menopausal women with osteoporosis. It is estimated that 50 percent of women and 20 percent of men over the age of 50 are at risk of a fragility fractures and less than 30% of patients are adequately treated with available medications.

“The data presented at ASBMR this year marks important progress for our EB613 program,” said Miranda Toledano, Chief Executive Officer of Entera. “Available injectable anabolic treatments, while efficacious and recommended across medical guidelines, are only accessible to a minority of patients globally. Our EB613 program is being developed to address the treatment chasm in osteoporosis care with a viable anabolic treatment in tablet format for patients to adequately protect their bones.”

In the oral presentation titled “Effects of EB613 Tablets [Oral PTH(1–34)] on Trabecular and Cortical Bone Using 3D–DXA: Results from Phase 2 Study,” Rachel B. Wagman, MD presented data using 3D–DXA modelling in a post–hoc analysis of EB613 Phase 2 results to look at the treatment’s impact on trabecular and cortical bone. After 6 months of treatment, EB613 2.5 mg demonstrated significant increases in both trabecular and cortical bone parameters as compared with placebo. Mechanistically, the findings suggest that bone strengthening, and fracture resistance may occur rapidly with EB613.

“The improvements across multiple parameters, including integral volumetric BMD, cortical thickness, and cortical surface BMD, suggest that there is an early strengthening effect with EB613 and a deterioration with placebo,” said Dr. Wagman. “We look forward to studying the safety and efficacy of EB613 in Phase 3.”

  • Increases in integral volumetric BMD of the TH and FN by 1.7% (p<0.08) and 2.6% (p<0.03), respectively
  • Increases in FN trabecular volumetric BMD by 4.4% vs. placebo (p<0.03) and increases in TH trabecular volumetric BMD by 2.8% (p=0.05 vs. baseline, NS compared with placebo)
  • Increases in cortical thickness at the TH and FN by 1.3% (p=0.04) and 1.7% (p=0.056), respectively Improvements in cortical surface BMD at the TH and FN by 1.5% and 2.1%, respectively (both p<0.05)

In a poster presentation titled “Advancing Oral Anabolic Treatments for Osteoporosis: Pre–Clinical Data for Next–Gen EB613 Tablet Utilizing N–Tab™ Proprietary Technology,” Entera presented preclinical data for its Next–Gen EB613 candidate. In a cross–over pharmacokinetic study in minipigs, a single 1.5 mg Next–Gen EB613 tablet demonstrated comparable PK to the current formulation of EB613, with identical AUClast and Tmax values (1.2 min*ng/ml and 20 min, respectively), and comparable Cmax. A Phase 1 clinical trial of Next–Gen EB613 is planned to begin in late 2025.

About EB613

Substantial evidence supports the efficacy of anabolic treatments over anti–resorptive drugs for lowering fracture risk in osteoporosis patients. However, all available anabolic therapies are administered by subcutaneous (SC) injection and used in a minority of eligible patients. EB613 (oral PTH (1–34)), is being developed as the first oral, once–daily anabolic tablet treatment for osteoporosis. EB613 completed a phase 2, 6–month, 161–patient, placebo–controlled study that met all biomarker and BMD endpoints without significant safety concerns in women with postmenopausal osteoporosis or low BMD (JBMR 2024). EB613 produced rapid dose–proportional increases in biochemical markers of bone formation, reductions in markers of bone resorption, and increased lumbar spine, total hip, and femoral neck BMD.

About Entera Bio

Entera is a clinical stage company focused on developing oral peptide and protein replacement therapies for significant unmet medical needs where an oral tablet form holds the potential to transform the standard of care. The Company leverages on a disruptive and proprietary technology platform (N–Tab™) and its pipeline of first–in–class oral peptide programs targeting PTH(1–34), GLP–1 and GLP–2. The Company’s most advanced product candidate, EB613 (oral PTH(1–34), teriparatide), is being developed as the first oral, osteoanabolic (bone building) once–daily tablet treatment for post–menopausal women with low BMD and high–risk osteoporosis. A placebo–controlled, dose–ranging Phase 2 study of EB613 tablets (n= 161) met primary (PD/bone turnover biomarker) and secondary endpoints (BMD). The EB612 program is being developed as the first oral PTH(1–34) tablet peptide replacement therapy for hypoparathyroidism. Entera is also developing the first oral oxyntomodulin, a dual targeted GLP1/glucagon peptide, in tablet form for the treatment of obesity and metabolic syndromes; and first oral GLP–2 peptide as an injection–free alternative for patients suffering from rare malabsorption conditions such as short bowel syndrome in collaboration with OPKO Health. For more information on Entera Bio, visit www.enterabio.com or follow us on LinkedIn, Twitter, and Facebook.

Cautionary Statement Regarding Forward Looking Statements

Various statements in this press release are “forward–looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements (other than statements of historical facts) in this press release regarding our prospects, plans, financial position, business strategy and expected financial and operational results may constitute forward–looking statements. Words such as, but not limited to, “anticipate,” “believe,” “can,” “could,” “expect,” “estimate,” “design,” “goal,” “intend,” “may,” “might,” “objective,” “plan,” “predict,” “project,” “target,” “likely,” “should,” “will,” and “would,” or the negative of these terms and similar expressions or words, identify forward–looking statements. Forward–looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. Forward–looking statements should not be read as a guarantee of future performance or results and may not be accurate indications of when such performance or results will be achieved. Important factors that could cause actual results to differ materially from those reflected in Entera's forward–looking statements include, among others: changes in the interpretation of clinical data; results of our clinical trials; the FDA's interpretation and review of our results from and analysis of our clinical trials; unexpected changes in our ongoing and planned preclinical development and clinical trials, the timing of and our ability to make regulatory filings and obtain and maintain regulatory approvals for our product candidates; the potential disruption and delay of manufacturing supply chains; loss of available workforce resources, either by Entera or its collaboration and laboratory partners; impacts to research and development or clinical activities that Entera may be contractually obligated to provide; overall regulatory timelines; the size and growth of the potential markets for our product candidates; the scope, progress and costs of developing Entera's product candidates; Entera's reliance on third parties to conduct its clinical trials; Entera's ability to establish and maintain development and commercialization collaborations; Entera's operation as a development stage company with limited operating history; Entera's competitive position with respect to other products on the market or in development for the treatment of osteoporosis, hypoparathyroidism, short bowel syndrome, obesity, metabolic conditions and other disease categories it pursues; Entera's ability to continue as a going concern absent access to sources of liquidity; Entera's ability to obtain and maintain regulatory approval for any of its product candidates; Entera's ability to comply with Nasdaq's minimum listing standards and other matters related to compliance with the requirements of being a public company in the United States; Entera's intellectual property position and its ability to protect its intellectual property; and other factors that are described in the “Cautionary Statement Regarding Forward–Looking Statements,” “Risk Factors” and “Management's Discussion and Analysis of Financial Condition and Results of Operations” sections of Entera's most recent Annual Report on Form 10–K filed with the SEC, as well as Entera's subsequently filed Quarterly Reports on Form 10–Q and Current Reports on Form 8–K. There can be no assurance that the actual results or developments anticipated by Entera will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Entera. Therefore, no assurance can be given that the outcomes stated or implied in such forward–looking statements and estimates will be achieved. Entera cautions investors not to rely on the forward–looking statements Entera makes in this press release. The information in this press release is provided only as of the date of this press release, and Entera undertakes no obligation to update or revise publicly any forward–looking statements, whether as a result of new information, future events or otherwise, except to the extent required by law.


GLOBENEWSWIRE (Distribution ID 9524990)

Sarborg Limited Closes $10 Million Seed Round to Expand Proprietary Agentic Approach

  • Funding supports next–generation AI agent development and proprietary Intellectual Property, focused initially on pharmaceutical drug–repurposing
  • Initial clients reporting commercial success, revolutionizing indication selection of lead programs
  • Early commercial success and key partnerships signal strong market traction and scalability potential into multiple commercial verticals

WILMINGTON, Del., Aug. 27, 2025 (GLOBE NEWSWIRE) — Sarborg Limited (“Sarborg” or the “Company”), a technology–driven company that integrates mathematical algorithm–led approaches with complementary cybernetics to optimize decision–making processes, is pleased to announce the successful closing of its $10 million Seed funding round, led by third–party investor, Corvus Capital.

Sarborg has achieved significant commercial and technical milestones from its development plan, since its inception in 2024. The issuance of $10 million of Convertible Promissory Notes highlights investor confidence in Sarborg’s novel approach and rapid development delivering commercial milestones.

Looking forward, the proceeds of the fundraising will enable Sarborg to scale its AI–driven drug development and deploy agents across expanded client portfolios, while diversifying its client and equity partnership base. Sarborg will continue to deepen its intellectual property portfolio and look to broaden its agentic approach to fields beyond pharmaceuticals.

Successful Launch and Strong Commercial Validation

Sarborg has quickly capitalized on early revenue–generation, with the successful execution of an initial services agreement with a NASDAQ–listed Pharmaceutical Company, validating its core technologies and a repurposing strategy based on their lead–program drug–signature model.

Sarborg has delivered personalized dashboards to clients, a critical tool designed to provide key personnel with real–time access to data related to deliverables, research and development oversight, and drug discovery. Furthermore, Sarborg has built a proprietary portfolio of over 800 disease signatures, each uniquely mapped using its proprietary data–driven approach and now focusing on an agentic–approach to repurposing without human intervention.

Proceeds from the fundraising will be strategically deployed to:

  • Advance Sarborg’s proprietary AI agents focused on drug repurposing, target identification, and clinical trial optimization.
  • Develop novel pharmaceutical IP, transforming underused molecules into novel IP through solid–form engineering and formulation expertise.
  • Grow Sarborg’s internal pipeline of pharmaceutical assets for monetization via outlicensing or royalty–based deal structures.
  • Expand the client base and revenue–generating service business to fund ongoing innovation and reduce dilution in future rounds.

Following the demand for its seed financing, the Company expects to shortly launch a follow–on Series A financing round to enable Sarborg to scale globally and solidify its position as a category leader in AI–driven agentic innovation, combining new equity, tokenized securities and crypto–based blockchain technologies across multiple verticals.

About Sarborg Limited

Sarborg is a technology–driven company that integrates proprietary AI–agents and mathematical algorithm–based approaches with complementary cybernetics and extensive neural networks, to optimize decision–making processes. Its current principal vertical is focused on evaluating drug repurposing matching unique drug and disease signatures for pharmaceutical companies, leveraging machine learning and algorithmic strategies to enhance asset portfolio management and improve the probability of success in clinical trials. The Company is planning its expansion into further analytic areas beyond pharmaceuticals.

The company is composed of a seasoned and highly experienced team in cybernetics and signature development, drug development, medical affairs and commercialization, regulatory affairs, IP and manufacturing. Since its inception in 2024, Sarborg has applied its suite of AI agents, cybernetic algorithms, and machine learning capabilities across various sectors, enabling a highly efficient decision–making process throughout its portfolio.

Investors & Media:
[email protected]
www.sarborg.com


GLOBENEWSWIRE (Distribution ID 9519004)

Extrovis AG and Dr. Reddy’s announce the launch of the authorized generic of CARAC (fluorouracil cream), 0.5% in the U.S.

                                      

Extrovis AG
Bahnhof Park 4
6340, Baar, Switzerland		 Media Relations Contact
Madhu Marur
[email protected]

                                        

Press Release

Extrovis AG and Dr. Reddy’s announce the launch of the authorized generic of CARAC (fluorouracil cream), 0.5% in the U.S.

Baar, Switzerland; August 14, 2025

Extrovis AG, a global pharmaceutical company focused on research–driven innovation, and Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy's”), today announced the launch of Fluorouracil Cream, 0.5%, an authorized generic and therapeutic equivalent of Carac® (fluorouracil cream) 0.5%, in the US market, approved by the U.S. Food and Drug Administration (USFDA).

Manufactured in Texas at one of Extrovis’ facilities, Dr. Reddy’s Fluorouracil Cream, 0.5%, is indicated for the topical treatment of multiple actinic or solar keratoses of the face and anterior scalp.

“This product generic launch marks a key milestone in our commitment to increasing patient access and long–term value creation for the U.S. healthcare system. Our partnership with Dr. Reddy’s helps ensure that patients and healthcare providers in the United States have continued access to a high–quality and cost–effective product,” said Hans R. Kamma Co–CEO and Chief Strategy Officer of Extrovis AG.

“Dr. Reddy’s brings deep expertise in commercialization and distribution within the U.S. market,” added Raghavendra Rao PV, Chief Financial Officer of Extrovis AG. “This collaboration is aligned with our mission to strengthen pharmaceutical supply chains and serve public health needs responsibly.”

The partnership reinforces Extrovis’ strategy to extend the reach of its therapeutics while advancing long–term affordability and sustainability in healthcare.

Dr. Reddy’s Fluorouracil Cream, 0.5%, is supplied in a 30–gram tube for topical use only. Please click here to see the full prescribing information.

                                                                                     

Carac® is a trademark of Extrovis AG

……………………………………………………………………………………..……………………………………………………………………………………………………………………

About Dr. Reddy’s
About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is a global pharmaceutical company headquartered in Hyderabad, India. Established in 1984, we are committed to providing access to affordable and innovative medicines. Driven by our purpose of ‘Good Health Can’t Wait’, we offer a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Our major markets include – USA, India, Russia & CIS countries, China, Brazil and Europe. As a company with a history of deep science that has led to several industry firsts, we continue to plan ahead and invest in businesses of the future. As an early adopter of sustainability and ESG actions, we released our first Sustainability Report in 2004. Our current ESG goals aim to set the bar high in environmental stewardship; access and affordability for patients; diversity; and governance. For more information, log on to: www.drreddys.com.

About Extrovis AG
Extrovis AG is a Switzerland–based global biopharmaceutical company committed to developing and commercializing high–quality therapies for unmet and under–addressed medical needs. With R&D and manufacturing operations in the USA, Italy, Hungary, and India, Extrovis delivers innovative, differentiated products across key therapeutic areas. Backed by strong R&D capabilities, regulatory expertise, and a robust global quality framework, the company advances its mission to improve patient outcomes and expand access to essential health care products worldwide. For more information, log on to: http://www.extrovis.com

………………………………………………………………………………………………………………………………………………………

Disclaimer: This press release may include statements of future expectations and other forward–looking statements that are based on the management’s current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward–looking by reason of context, the words “may”, “will”, “should”, “expects”, “plans”, “intends”, “anticipates”, “believes”, “estimates”, “predicts”, “potential”, or “continue” and similar expressions identify forward–looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults , currency exchange rates, interest rates, persistency levels and frequency / severity of insured loss events, (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization, including related integration issues, and (vi) the susceptibility of our industry and the markets addressed by our, and our customers’, products and services to economic downturns as a result of natural disasters, epidemics, pandemics or other widespread illness, including coronavirus (or COVID–19). The company assumes no obligation to update any information contained herein.

 

Attachment


GLOBENEWSWIRE (Distribution ID 1001123392)

EAACI lança campanha global de conscientização sobre alergia a antibióticos no Congresso EAACI 2025 (EAACI Congress 2025)

ZURIQUE, Aug. 15, 2025 (GLOBE NEWSWIRE) — A EAACI lançou sua Campanha de Conscientização sobre Alergia a Antibióticos durante seu Congresso de 2025, realizado em Glasgow. A iniciativa dá início a um esforço global para abordar a rotulagem incorreta e sua ligação com a resistência antimicrobiana (RAM).

Uma chamada global à ação

A rotulagem incorreta de alergias a antibióticos afeta milhões de pessoas no mundo todo. Informações incorretas nos rótulos resultam na evitação de tratamentos de primeira linha e no uso excessivo de antibióticos de segunda linha, alimentando a RAM. A EAACI faz um apelo a todas as partes interessadas para que promovam o diagnóstico preciso e o uso responsável de antibióticos.

“Estamos lançando um movimento — não um momento”, declarou Maria Torres, presidente da EAACI. “Muitas vidas são impactadas pela não verificação das informações sobre alergias em rótulos, limitando as opções de tratamento e piorando os resultados em termos de saúde. Esta campanha cria uma dinâmica que favorece a correção de rótulos, uma melhora na segurança e a preservação dos antibióticos para as gerações futuras. Corrigir as informações dos rótulos significa salvar vidas — hoje e amanhã.”

Objetivos da campanha:

  • Ampliar a conscientização sobre os perigos da rotulagem incorreta de alergias a antibióticos
  • Capacitar os pacientes e profissionais de saúde com ferramentas e treinamento
  • Promover protocolos de avaliação de alergias amparados em evidências
  • Incentivar a prescrição racional dos antibióticos, a fim de proteger a eficácia em longo prazo

Superar os obstáculos

Muitos pacientes mantêm rótulos de alergia desatualizados, não verificados ou relatados pelos próprios pacientes, o que diminui as opções de tratamento e aumenta os riscos. A campanha aborda essas questões por meio de educação, treinamento e defesa dos direitos.

Recursos para impulsionar as mudanças

Um destaque central da campanha é um breve vídeo educativo que explica as alergias a antibióticos e por que as informações corretas em rótulos são importantes. O Kit Promocional 2025 oferece ferramentas para ampliar a campanha em todas as plataformas.

Junte–se ao movimento

Lançada sob o slogan “Correct Labels, Better Lives” (Rótulos corretos, vidas melhores), a campanha convida profissionais, educadores, instituições e indivíduos a se juntarem a este esforço global de conscientização. Juntos, podemos proteger a eficácia dos antibióticos.

Explore a campanha e baixe os recursos: https://eaaci.org/eaaci–antibiotic–allergy–awareness–campaign/

Sobre a EAACI

A Academia Europeia de Alergia e Imunologia Clínica (The European Academy of Allergy and Clinical Immunology, EAACI) é a maior associação profissional da Europa na área, comprometida em promover a pesquisa e o tratamento de pessoas afetadas por doenças alérgicas.

Saiba mais em https://eaaci.org

Contato: [email protected] | +41 44 205 55 33

Uma foto que acompanha este anúncio está disponível em http://www.globenewswire.com/NewsRoom/AttachmentNg/f2d7cd4b–652b–4207–9c07–315528446450


GLOBENEWSWIRE (Distribution ID 1001122910)

EAACI startet globale Aufklärungskampagne zu Antibiotikaallergien auf dem EAACI-Kongress 2025 (EAACI Congress 2025)

ZÜRICH, Aug. 15, 2025 (GLOBE NEWSWIRE) — Die EAACI hat im Rahmen ihres Kongresses 2025 in Glasgow ihre Aufklärungskampagne zum Thema Antibiotikaallergien gestartet. Die Initiative ist der Beginn einer weltweiten Kampagne gegen falsche Kennzeichnung und deren Zusammenhang mit Antibiotikaresistenzen (AMR).

Ein weltweiter Aufruf zum Handeln

Die falsche Kennzeichnung von Antibiotika–Allergien betrifft Millionen Menschen weltweit. Ungenaue Kennzeichnungen führen dazu, dass Erstlinienbehandlungen vermieden und Zweitlinienantibiotika übermäßig eingesetzt werden, was die AMR begünstigt. Die EAACI fordert alle Stakeholder auf, eine genaue Diagnose und einen verantwortungsvollen Einsatz von Antibiotika sicherzustellen.

„Wir starten eine Bewegung – nicht nur eine Momentaufnahme“, erklärte Maria Torres, Präsidentin der EAACI. „Zu viele Leben werden durch unbestätigte Allergiehinweise beeinträchtigt, die die Behandlungsmöglichkeiten einschränken und die Gesundheitsergebnisse verschlechtern. Diese Kampagne schafft Impulse, um Kennzeichnungen zu korrigieren, die Sicherheit zu verbessern und Antibiotika für künftige Generationen zu erhalten. Beschriftungen zu korrigieren bedeutet, Leben zu retten – jetzt und in Zukunft.“

Die Ziele der Kampagne:

  • Sensibilisierung für die Gefahren falscher Angaben zu Antibiotikaallergien
  • Stärken der Patienten und des medizinischen Fachpersonals mit Tools und Schulungen
  • Förderung evidenzbasierter Protokolle zur Allergieuntersuchung
  • Förderung einer rationalen Verschreibung von Antibiotika zum Schutz der langfristigen Wirksamkeit

Barrieren überwinden

Viele Patienten tragen veraltete, nicht verifizierte oder selbst erstellte Allergiehinweise bei sich, was die Behandlungsmöglichkeiten einschränkt und das Risiko erhöht. Die Kampagne befasst sich mit diesen Themen durch Aufklärung, Schulungen und Interessenvertretung.

Ressourcen für Veränderungen

Ein zentraler Bestandteil der Kampagne ist ein kurzes Informationsvideo, in dem Antibiotikaallergien erklärt werden und dargelegt wird, warum korrekte Kennzeichnungen wichtig sind. Das Werbekit 2025 enthält Instrumente, mit denen die Kampagne auf allen Plattformen verstärkt werden kann.

Werden Sie Teil der Bewegung

Die Kampagne wurde unter dem Motto „Correct Labels, Better Lives” (Korrekte Kennzeichnungen, besseres Leben) ins Leben gerufen und lädt Fachleute, Pädagogen, Institutionen und Einzelpersonen dazu ein, sich den weltweiten Bemühungen zur Sensibilisierung anzuschließen. Gemeinsam können wir die Wirksamkeit von Antibiotika schützen.

Entdecken Sie die Kampagne und laden Sie Ressourcen herunter: https://eaaci.org/eaaci–antibiotic–allergy–awareness–campaign/

Über die EAACI

Die Europäische Akademie für Allergien und klinische Immunologie (The European Academy of Allergy and Clinical Immunology, EAACI) ist Europas größter Berufsverband in diesem Bereich und engagiert sich für die Förderung der Forschung und Versorgung von Menschen, die von allergischen Erkrankungen betroffen sind.

Erfahren Sie mehr: https://eaaci.org

Kontakt: [email protected] | +41 44 205 55 33

Ein Foto zu dieser Mitteilung finden Sie unter http://www.globenewswire.com/NewsRoom/AttachmentNg/f2d7cd4b–652b–4207–9c07–315528446450


GLOBENEWSWIRE (Distribution ID 1001122910)

EAACI Launches Global Antibiotic Allergy Awareness Campaign at EAACI Congress 2025

ZURICH, Aug. 15, 2025 (GLOBE NEWSWIRE) — EAACI has launched its Antibiotic Allergy Awareness Campaign during its 2025 Congress in Glasgow. The initiative begins a global effort to address mislabelling and its link to antimicrobial resistance (AMR).

A Global Call to Action

Antibiotic allergy mislabelling affects millions worldwide. Inaccurate labels lead to avoidance of first–line treatments and overuse of second–line antibiotics, fuelling AMR. EAACI calls on all stakeholders to promote accurate diagnosis and responsible antibiotic use.

“We are launching a movement — not a moment,” said Maria Torres, EAACI President. “Too many lives are impacted by unverified allergy labels that limit treatment options and worsen health outcomes. This campaign builds momentum to correct labels, improve safety, and preserve antibiotics for future generations. Correcting labels means saving lives — now and in the future.”

The Campaign's Objectives:

  • Raise awareness about the dangers of incorrect antibiotic allergy labels
  • Empower patients and healthcare professionals with tools and training
  • Promote evidence–based allergy evaluation protocols
  • Encourage rational antibiotic prescribing to protect long–term efficacy

Breaking Down the Barriers

Many patients carry outdated, unverified, or self–reported allergy labels, reducing treatment options and increasing risk. The campaign tackles these issues through education, training, and advocacy.

Resources to Drive Change

A central feature of the campaign is a short educational video explaining antibiotic allergy and why correct labels matter. The Promotional Kit 2025 offers tools to amplify the campaign across all platforms.

Join the Movement

Launched under the slogan “Correct Labels, Better Lives,” the campaign invites professionals, educators, institutions, and individuals to join the global awareness effort. Together, we can protect the effectiveness of antibiotics.

Explore the campaign and download resources: https://eaaci.org/eaaci–antibiotic–allergy–awareness–campaign/

About EAACI

The European Academy of Allergy and Clinical Immunology (EAACI) is Europe’s largest professional association in the field, committed to advancing research and care for those affected by allergic diseases.

Learn more: https://eaaci.org

Contact: [email protected] | +41 44 205 55 33

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/f2d7cd4b–652b–4207–9c07–315528446450


GLOBENEWSWIRE (Distribution ID 1001122912)

L’EAACI lance une campagne mondiale de sensibilisation aux allergies aux antibiotiques lors du EAACI Congress 2025

ZURICH, 15 août 2025 (GLOBE NEWSWIRE) — L’EAACI a lancé sa Antibiotic Allergy Awareness Campaign (Campagne de sensibilisation aux allergies aux antibiotiques) à l’occasion de son Congrès 2025 à Glasgow. Cette initiative marque le début d’un effort mondial visant à lutter contre les erreurs d’étiquetage et son lien avec la résistance aux antimicrobiens (RAM).

Un appel mondial à l’action

Les erreurs d’étiquetage relatives aux allergies aux antibiotiques touchent des millions de personnes dans le monde. Des mentions erronées conduisent à éviter les traitements de première intention et à surutiliser les antibiotiques de deuxième intention, favorisant ainsi la RAM. L’EAACI appelle l’ensemble des acteurs à promouvoir un diagnostic précis et un usage responsable des antibiotiques.

« Nous entamons une action à long terme, et non une initiative ponctuelle », a déclaré Maria Torres, présidente de l’EAACI. « Trop de vies sont affectées par des étiquettes d’allergie non vérifiées qui limitent les options de traitement et aggravent les résultats en matière de santé. Cette campagne vise à corriger ces étiquettes, améliorer la sécurité et préserver les antibiotiques pour les générations futures. Rectifier ces étiquettes, c’est sauver des vies, aujourd’hui et demain. »

Les objectifs de la campagne :

  • Sensibiliser aux dangers des mentions incorrectes d’allergie aux antibiotiques
  • Donner aux patients et aux professionnels de santé des outils et formations adaptés
  • Promouvoir des protocoles d’évaluation des allergies fondés sur des données probantes
  • Encourager une prescription raisonnée des antibiotiques afin d’en préserver l’efficacité à long terme

Faire tomber les barrières

De nombreux patients disposent d’étiquettes d’allergie obsolètes, non vérifiées ou auto–déclarées, qui limitent leurs options de traitement et augmentent les risques. La campagne cible ces problèmes par le biais de l’éducation, de la formation et de la sensibilisation.

Des ressources pour stimuler le changement

L’un des éléments clés de la campagne consiste en une courte vidéo éducative qui rappelle ce qu’est l’allergie aux antibiotiques et pourquoi il est crucial de disposer d’étiquettes adéquates. Le Promotional Kit 2025 met à disposition des outils pour promouvoir la campagne sur tous les canaux.

Rejoignez le mouvement

Lancées sous le slogan « Correct Labels, Better Lives » (Des étiquettes correctes, une vie meilleure), les actions de la campagne invitent professionnels, enseignants, institutions et particuliers à s’engager dans cette mobilisation mondiale. Ensemble, nous pouvons protéger l’efficacité des antibiotiques.

Découvrez la campagne et téléchargez les ressources : https://eaaci.org/eaaci–antibiotic–allergy–awareness–campaign/

À propos de l’EAACI

La Académie européenne d’allergologie et d’immunologie clinique (The European Academy of Allergy and Clinical Immunology, EAACI) est la plus grande association professionnelle européenne de ces domaines thérapeutiques. Elle s’engage à faire progresser la recherche et les soins pour les personnes atteintes de maladies allergiques.

Pour en savoir plus, rendez–vous sur https://eaaci.org

Cordonnées : [email protected] | +41 44 205 55 33

Une photo annexée au présent communiqué est disponible à l’adresse suivante : http://www.globenewswire.com/NewsRoom/AttachmentNg/f2d7cd4b–652b–4207–9c07–315528446450


GLOBENEWSWIRE (Distribution ID 1001122910)

Healthcare Innovation Summit Africa Returns to Johannesburg – Registration Now Open

JOHANNESBURG, South Africa, Aug. 14, 2025 (GLOBE NEWSWIRE) — The Healthcare Innovation Summit Africa (HISA) 2025, Africa’s leading platform for exploring the latest trends and technologies shaping the healthcare industry, will return to Johannesburg on 22 – 23 October 2025 for its 10th annual edition. Organised by IT News Africa, the event will gather senior healthcare professionals, government leaders, innovators, and technology providers from across Africa and beyond.

Themed “Connected Care, Smarter Systems: Building a Digitally Resilient African Health Ecosystem,” HISA 2025 will feature a robust agenda that covers critical areas such as artificial intelligence (AI), the Internet of Things (IoT), robotics, telemedicine, big data analytics, and digital transformation strategies for both public and private healthcare sectors.

Confirmed keynote and panel speakers include:

  • Dr Richard Friedland, Group CEO, Netcare
  • Dr. Boris Konrad, Neuroscientist, AI and Memory Expert, Radboudumc (Germany)
  • Andrew Raynes, CIO & SIRO, Royal Papworth Hospital (UK)
  • Nhlanhla Xaba, ICT Manager: Governance & Information Management, Mediclinic
  • Rajeev Eashwari, President, South African Health Informatics Association
  • Taryn Lotz, Head of IT, Aspen Pharmacare
  • Craig Killeen, CEO, Medinformer
  • Joost Pielage, CTO, Quro Medical
  • Quantin van Rensburg, CIO, Platinum Health Medical Scheme
  • Ish Hendricks, CEO, Netclinic

With Africa’s healthcare industry undergoing rapid transformation, HISA 2025 offers a unique opportunity for stakeholders to gain actionable insights and forge meaningful partnerships.

Delegates will benefit from:

  • Visionary keynote presentations from local and international thought leaders
  • Expert–led panel discussions tackling pressing healthcare challenges and opportunities
  • Exhibition showcases of innovative solutions, products, and services
  • Networking opportunities with policymakers, industry leaders, and innovators

Click here to register now

“HISA 2025 is not just a conference, it is where the future of African healthcare takes shape,” said the event organisers. “The event provides a powerful platform for collaboration, innovation, and the exchange of ideas that can positively impact healthcare systems across the continent.”

Event Details:
Date: 22 – 23 October 2025
Venue: Gallagher Convention Centre, Johannesburg, South Africa
Event Website: www.healthcareinnovationsummit.co.za

About HISA
The Healthcare Innovation Summit Africa is an annual gathering of healthcare professionals, innovators, and policymakers dedicated to exploring and implementing technology–driven solutions that improve healthcare delivery across Africa.


GLOBENEWSWIRE (Distribution ID 1001122873)